Logo image of BIOR

BIORA THERAPEUTICS INC (BIOR) Stock Fundamental Analysis

NASDAQ:BIOR - Nasdaq - US74319F3055 - Common Stock - Currency: USD

0.5597  -0.79 (-58.54%)

After market: 0.579 +0.02 (+3.45%)

Fundamental Rating

2

Taking everything into account, BIOR scores 2 out of 10 in our fundamental rating. BIOR was compared to 558 industry peers in the Biotechnology industry. BIOR has a bad profitability rating. Also its financial health evaluation is rather negative. BIOR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BIOR has reported negative net income.
BIOR had a negative operating cash flow in the past year.
In the past 5 years BIOR always reported negative net income.
BIOR had a negative operating cash flow in each of the past 5 years.
BIOR Yearly Net Income VS EBIT VS OCF VS FCFBIOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M

1.2 Ratios

BIOR has a Return On Assets of -217.44%. This is amonst the worse of the industry: BIOR underperforms 91.15% of its industry peers.
Industry RankSector Rank
ROA -217.44%
ROE N/A
ROIC N/A
ROA(3y)-232.13%
ROA(5y)-209.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BIOR Yearly ROA, ROE, ROICBIOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K

1.3 Margins

BIOR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIOR Yearly Profit, Operating, Gross MarginsBIOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -1M -2M -3M

More info and screens

1

2. Health

2.1 Basic Checks

BIOR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BIOR has less shares outstanding
The number of shares outstanding for BIOR has been increased compared to 5 years ago.
The debt/assets ratio for BIOR has been reduced compared to a year ago.
BIOR Yearly Shares OutstandingBIOR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
BIOR Yearly Total Debt VS Total AssetsBIOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

BIOR has an Altman-Z score of -116.59. This is a bad value and indicates that BIOR is not financially healthy and even has some risk of bankruptcy.
BIOR's Altman-Z score of -116.59 is on the low side compared to the rest of the industry. BIOR is outperformed by 98.05% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -116.59
ROIC/WACCN/A
WACC2.47%
BIOR Yearly LT Debt VS Equity VS FCFBIOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M

2.3 Liquidity

A Current Ratio of 0.05 indicates that BIOR may have some problems paying its short term obligations.
BIOR has a worse Current ratio (0.05) than 99.29% of its industry peers.
A Quick Ratio of 0.05 indicates that BIOR may have some problems paying its short term obligations.
The Quick ratio of BIOR (0.05) is worse than 99.29% of its industry peers.
Industry RankSector Rank
Current Ratio 0.05
Quick Ratio 0.05
BIOR Yearly Current Assets VS Current LiabilitesBIOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for BIOR have decreased strongly by -22.72% in the last year.
BIOR shows a strong growth in Revenue. In the last year, the Revenue has grown by 8820.00%.
Measured over the past years, BIOR shows a very negative growth in Revenue. The Revenue has been decreasing by -87.44% on average per year.
EPS 1Y (TTM)-22.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.69%
Revenue 1Y (TTM)8820%
Revenue growth 3Y-72.86%
Revenue growth 5Y-87.44%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 24.30% on average over the next years. This is a very strong growth
BIOR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 933.87% yearly.
EPS Next Y88.79%
EPS Next 2Y38.19%
EPS Next 3Y24.3%
EPS Next 5YN/A
Revenue Next Year39100%
Revenue Next 2Y3064.14%
Revenue Next 3Y933.87%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BIOR Yearly Revenue VS EstimatesBIOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M
BIOR Yearly EPS VS EstimatesBIOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -500 -1K -1.5K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BIOR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BIOR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIOR Price Earnings VS Forward Price EarningsBIOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIOR Per share dataBIOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

BIOR's earnings are expected to grow with 24.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.19%
EPS Next 3Y24.3%

More info and screens

0

5. Dividend

5.1 Amount

BIOR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIORA THERAPEUTICS INC

NASDAQ:BIOR (12/10/2024, 8:09:45 PM)

After market: 0.579 +0.02 (+3.45%)

0.5597

-0.79 (-58.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)N/A N/A
Inst Owners38.19%
Inst Owner Change-0.01%
Ins Owners0.61%
Ins Owner Change0%
Market Cap2.53M
Analysts82.86
Price Target34.68 (6096.18%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)55.44%
Min EPS beat(2)-28.34%
Max EPS beat(2)139.22%
EPS beat(4)2
Avg EPS beat(4)44.55%
Min EPS beat(4)-28.34%
Max EPS beat(4)139.22%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)248.72%
EPS NQ rev (1m)10.81%
EPS NQ rev (3m)-695.18%
EPS NY rev (1m)-2.43%
EPS NY rev (3m)-924.29%
Revenue NQ rev (1m)-54.55%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-23.46%
Revenue NY rev (3m)-23.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.84
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-10.84
EYN/A
EPS(NY)-7.46
Fwd EYN/A
FCF(TTM)-10.22
FCFYN/A
OCF(TTM)-10.16
OCFYN/A
SpS0.2
BVpS-23.59
TBVpS-24.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -217.44%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-232.13%
ROA(5y)-209.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 62.81%
Cap/Sales 31.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.05
Quick Ratio 0.05
Altman-Z -116.59
F-Score4
WACC2.47%
ROIC/WACCN/A
Cap/Depr(3y)55.03%
Cap/Depr(5y)64.29%
Cap/Sales(3y)970%
Cap/Sales(5y)1076.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-22.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.69%
EPS Next Y88.79%
EPS Next 2Y38.19%
EPS Next 3Y24.3%
EPS Next 5YN/A
Revenue 1Y (TTM)8820%
Revenue growth 3Y-72.86%
Revenue growth 5Y-87.44%
Sales Q2Q%N/A
Revenue Next Year39100%
Revenue Next 2Y3064.14%
Revenue Next 3Y933.87%
Revenue Next 5YN/A
EBIT growth 1Y9.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.32%
EBIT Next 3Y-5.74%
EBIT Next 5YN/A
FCF growth 1Y50.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.85%
OCF growth 3YN/A
OCF growth 5YN/A